Literature DB >> 12753417

Hypertension due to blockade of adenosine receptors.

Serafim Guimarães1, Manuela Morato, Teresa Sousa, António Albino-Teixeira.   

Abstract

Chronic treatment of rats with 90 microg/kg/day DPSPX (1,3-dipropyl-8-sulphophenylxanthine) during seven days leads to a hypertensive state which is characterized by marked morphological changes of the blood vessel walls as well as by important functional alterations. While the angiotensin-converting enzyme (ACE) inhibitor captopril and the antagonist of angiotensin II AT 1 receptors losartan prevent the development of both hypertension and morphological changes, the selective beta1-adrenoceptor antagonist atenolol could prevent only the increase in blood pressure. It is concluded that at least two factors are involved in the development of the hypertensive state.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753417     DOI: 10.1034/j.1600-0773.2003.920404.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  3 in total

1.  A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta.

Authors:  Serafim Guimarães; Catarina Carneiro; Fernando Brandão; Helder Pinheiro; António Albino-Teixeira; Daniel Moura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-23       Impact factor: 3.000

2.  Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive.

Authors:  Elvira L Liclican; Anabel B Doumad; Jianjin Wang; Jing Li; John R Falck; Charles T Stier; Mairéad A Carroll
Journal:  Hypertension       Date:  2009-10-12       Impact factor: 10.190

3.  Impaired function of prejunctional adenosine A1 receptors expressed by perivascular sympathetic nerves in DOCA-salt hypertensive rats.

Authors:  Sutheera Sangsiri; Hua Dong; Gregory M Swain; James J Galligan; Hui Xu
Journal:  J Pharmacol Exp Ther       Date:  2013-02-08       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.